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Abstract
Observational studies have shown that low serum levels of vitamin D have been associated with an atherogenic
lipid profile. However, the intervention studies gave divergent results. We conducted a meta-analysis of
randomized controlled trials that evaluated the effects of vitamin D supplementation on blood lipids. A systematic
literature search was conducted via MEDLINE, Cochrane library, and EMBASE for randomized controlled clinical trials
assessing the effects of vitamin D supplementation on lipids. The mean change in total cholesterol (TC), low-
density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C) and triglycerides (TG) from
baseline was treated as a continuous variable. In all, 12 clinical trials consisting of 1346 participants were included
in the analysis. The pooled estimate of effect for vitamin D supplementation on LDL-C was 3.23 mg/dl (95%
confidence interval, 0.55 to 5.90 mg/dl). No statistically significant effects for vitamin D supplementation were
observed for TC, HDL-C and TG (differences in means were 1.52 mg/dl (-1.42 to 4.46 mg/dl), -0.14 mg/dl (-0.99 to
0.71 mg/dl) and -1.92 mg/dl (-7.72 to 3.88 mg/dl) respectively). The lipid modulating effects of vitamin D
supplementation should be further investigated though large-scale, randomized trials with adequate doses which
can effectively elevated the active form of vitamin D in plasma and with proper population which has
hyperlipemia as an inclusion criterion.
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Introduction
Cardiovascular disease (CVD) remains the leading cause
of death and disability in the world [1]. Although cardi-
ovascular mortality rates have declined in some high-
income countries, more than 17 million people died
from CVD in 2008 and it is estimated that by 2030,
almost 23.6 million people will die from CVD. Thus,
extraordinary effort has been devoted to determining
the modifying risk factors to prevent atherosclerosis, the
main cause of CVD. There is now increasing evidence
that vitamin D, beyond its well-known effects on bone
metabolism, also plays an important role in the develop-
ment of CVD [2]. Epidemiologic studies have shown
that vitamin D deficiency was closely associated with
increased risk of major adverse CVD events [3,4].
Furthermore, randomized intervention trials showed a
tendency towards a reduction in CVD risk with vitamin
D supplementation, though the tendency is statistically
nonsignificant [5]. Taking into account that vitamin D
deficiency is highly prevalent across the world while
vitamin D supplementation is simple, safe, and inexpen-
sive [6], the deficiency of vitamin D may be a common
and easily treatable risk factor for CVD prevention [7].
There are several possible mechanisms contributing to
the association between vitamin D and CVD, such as
insulin sensitivity, parathyroid hormone elevation and
inflammation [8]. It is reasonable that dyslipidemia
should also be considered as a potential link because
dyslipidemia is a well-described independent risk factor
for CVD. Observational studies have indicated that high
25-hydroxyvitamin D [25(OH)D] levels were associated
with a favorable serum lipid profile [9]. However, a solid
rationale for such association is difficult to determine
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on serum lipids in placebo-controlled randomized trials.
Unfortunately, the intervention studies gave divergent
r e s u l t st h a ts o m es h o w i n gap o s i t i v ea n ds o m ean e g a -
tive effect [9]. Therefore, we conducted a meta-analysis
of randomized controlled trials to evaluate the potential
effect of vitamin D supplem e n t a t i o no ns e r u ml i p i d
profiles.
Methods
Search strategy and study selection
A systematic search of the literature published prior to
November 2011 was conducted in MEDLINE, Cochrane
library, and EMBASE to identify all articles related to
randomized controlled trials examining the effect of
vitamin D supplementation on the blood lipid profile.
The following key words were used in all fields: (vitamin
D OR 25-hydroxyvitamin D OR vitamin D3 OR chole-
calciferol OR ergocalciferol OR calcifediol OR calcitriol)
AND (lipids OR cholesterol OR triglycerides OR HDL
OR LDL OR apolipoprotein A OR apolipoprotein B).
No language and time restrictions were imposed and no
attempt was made to include abstracts or unpublished
studies. Then, duplicate citations were removed. In addi-
tion, a manual search of references from primary or
review articles was performed to identify relevant trials.
Trials were included in the analysis if they were rando-
mized controlled trials of vitamin D in human partici-
pants in which the mean changes of total cholesterol
(TC), low-density lipoprotein cholesterol (LDL-C), high-
density lipoprotein cholesterol (HDL-C) and triglycerides
(TG) concentration, along with standard deviation, were
reported for the intervention and control groups. Studies
where vitamin D was combined with calcium were only
included if the placebo group was given the same calcium
supplement. Furthermore, we excluded studies in which
vitamin intake was mixed with other dietary treatments
or drugs. We excluded studies that focused on the
patients with non-cardiovascular diseases, such as
chronic kidney disease, hemodialysis states and rheuma-
toid arthritis for the reason that these diseases have
remarkable impact on lipids profile and might confused
the effects of vitamin D supplement on lipids. In trials for
which there was more than one published report on the
same population of patients, the most recent publication
was selected for analysis. Trials involving more than one
intervention group were included by entering each pair-
wise comparison into the meta-analysis as separate trials,
but with the repeated control groups’ sample size divided
out evenly among the comparisons.
Data extraction and quality assessment
Two investigators (HW and NX) performed the data
extraction independently. In case of disagreement, a
third investigator was consulted (DQP). Discrepancies
were resolved by consensus. The following information
was abstracted from eligible articles: first author’s name;
year of publication; number and age range of partici-
pants; study design; vitamin D type and dose used; dura-
tion of study; health conditions of the study population.
We also extracted information on the baseline and final
concentrations (or net changes) of serum total choles-
terol (TC), LDL cholesterol, HDL cholesterol, and trigly-
cerides (TG).
The quantitative 5-point Jadad score system was used
to assess the strength of included studies [10]. This
included independent assessments by two investigators
(HW and NX) of factors referring the description of
randomization, double blinding, and drop-outs.
Data synthesis and statistical analysis
The mean change in each lipid parameter was the out-
come of interest in this meta-analysis. Studies that
reported results in mmol/l were converted to mg/dl.
The conversion factor was 1 mg/dl = 0.0259 mmol/l for
TC, HDL and LDL; and 1 mg/dl = 0.0113 mmol/l for
TG. Standard errors were converted to standard devia-
tion for the analyses. Studies not reporting standard
deviations or standard errors were excluded.
T h em e a nc h a n g ei ne a c hl i p id parameter from base-
line was treated as a continuous variable. Some studies
reported only mean values with standard deviations of
the baseline and endpoint for the paired groups. In this
condition, net changes for the lipid parameters were cal-
culated as the difference (intervention minus control) of
the changes (endpoint minus baseline) in mean values.
Standard deviation was calculated from the variances of
baseline and endpoint using a correlation coefficient of
0.5[11].
SD(difference) =[ ( S D 2 (intervention) +S D 2 (control)
− 2 × 0.5 × SD (intervention) × SD (control)]1/2
Statistical heterogeneity was addressed using Cochrane
Q test, and the magnitude of heterogeneity was esti-
mated by I
2 statistic. Visual inspection of funnel plots
was used to assess for the presence of publication bias.
Results
A total of 1384 articles were found in our initial search,
1347 of which could be excluded by screening the titles
or abstracts. A further 13 articles were excluded because
they did not report sufficient details on blood lipid para-
meters. Among them, one study met all our inclusion
criteria but could not be incorporated into the meta-
analysis because it reported quartiles instead of variance
[12]. 5 more trials were excluded because vitamin D was
a part of mixed intervention [13-17]. Other 4 studies
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dialysis patients [18-21]. A flow diagram on articles
selection for this meta-analysis is shown in Figure 1.
In all, 10 articles matched for our inclusion criterion
[22-31]. The studies performed by Jorde et al. [27] and
Witham et al. [28] involved two intervention groups
respectively and we included each pair-wise comparison
into the meta-analysis as separate trials. Therefore, 12
randomized controlled trials were included in our meta-
analysis. Characteristics of included studies are pre-
sented in Table 1. All of the trials were double-blind,
randomized and controlled clinical studies with parallel
design. Eight of the studies obtained a Jadad score of >
3. The selected trials involved 1346 individuals in total,
ranging in age from 18 to 80 years. Four of the studies
[23-25,31] were conducted on healthy subjects and three
others [26,27,30] were carried out on obese subjects.
Other two studies [22,28] involved diabetic patients and
one study [29] involved patients with a history of stroke.
Adherence varied between 75% and 100%, with eleven
out of twelve trials reporting adherence of 80-100%.
Vitamin D3/cholecalciferol was used in seven studies
and other studies used alpha-calcidol, calcitriol or ergo-
calciferol. In studies which administered a daily dose of
vitamin D supplement, the dose ranged from 300 IU to
3332 IU. Furthermore, two trials administered a single
Figure 1 Flow diagram of study selection process.
Table 1 Characteristics of the enrolled references in the meta-analysis
Trial Design Sample
size
Age
range
(yrs)
Population
characteristics
Duration Intervention Control Outcomes Jadad
quality
grades (0-
5)
Ljunghall et al.
(1987)
Parallel 65 61-65 Middle-aged men with
impaired glucose
tolerance; Swedish
12 weeks 0.75 ug alpha-calcidol,
daily
placebo TC, HDL,
TG
1
Heikkinen et al.
(1997)
Parallel 178 47-56 Postmenopausal women;
Finnish
3 years 300 IU cholecalciferol
+500 mg calcium lactate,
daily
500 mg
calcium
lactate
TC, LDL,
HDL, TG
2
Pfeifer et al.
(2001)
Parellel 148 74 ± 1 Elderly women with low
vitamin D status; German
8 weeks 800 IU vitamin D3+1200
mg calcium, daily
1200 mg
calcium
TC 4
Nagpal et al.
(2009)
Parallel 71 ≥ 35 Middle-aged healthy men
with central obesity;
Indian
42 days 120000 IU cholecalciferol,
fortnightly
placebo TC, LDL,
HDL, TG
5
Zittermann
et al. (2009)
Parallel 165 48 ±
10
Healthy overweight
subjects; German
1 year 3332 IU cholecalciferol,
daily
placebo LDL, HDL,
TG
5
Jorde et al.
(a/b) (2010)
Parallel 216/226 21-70 Overweight and obese
subjects; Norwegian
1 year 20000/40000 IU
cholecalciferol weekly
+500 mg calcium daily
500 mg
calcium
TC, LDL,
HDL, TG
4
Witham et al.
(a/b) (2010)
Parallel 40/39 65 ±
10
Patients with type 2
diabetes; Scottish
16 weeks 100000/200000 IU vitamin
D3, once
placebo TC 5
Witham et al.
(2010)
Parallel 58 67 ±
10
Patients with a history of
stroke; Scottish
16 weeks 100000 IU ergocalciferol
once
placebo TC 5
Maki et al.
(2011)
Parallel 60 18-79 Subjects with high waist
circumference; American
8 weeks 1200 IU cholecalciferol
+MVM (multivitamin and
mineral), daily
MVM TC, LDL,
HDL, TG
5
Sai et al.
(2011)
Parallel 213 65-77 Postmenopausal women;
American
3 years 0.5 ug calcitriol, daily placebo TC, LDL,
HDL, TG
4
TC, total cholesterol; HDL, high density lipoprotein cholesterol; LDL, low density lipoprotein cholesterol; TG, triglycerides
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nistered a supplement fortnightly [25,28,29]. The dura-
tion of the intervention ranged from 42 days to 3 years.
Calcium supplementation was used in both treatment
and placebo groups in four trials, and the dose varied
between 500 mg/day and 1200 mg/day. Data of initial
25(OH)D levels as well as achieved 25(OH)D levels were
available in ten of the trials. Most of the studies showed
that the intake of vitamin D supplements resulted in
increases in serum 25(OH)D levels (Table 2).
The pooled mean net change in LDL-C concentration
(95% CI) comparing vitamin D supplement with placebo
was statistically significant as 3.23 mg/dl (0.55, 5.90)
(Figure 2). Corresponding changes for TC, HDL-C and
TG were 1.52 mg/dl (-1.42, 4.46) (Figure 3), -0.14 mg/dl
(-0.99, 0.71) (Figure 4) and -1.92 mg/dl (-7.72, 3.88)
(Figure 5), respectively. No statistical heterogeneity was
observed in any of the lipid parameter analyses. Total
cholesterol, LDL-C, HDL-C and triglycerides had I
2
values of 0%, 21%, 16% and 46%, respectively.
Subgroup analysis were carried out with the data segre-
gated by location (high latitude vs. middle and low lati-
tude areas), interventional duration (> 1 year and ≤ 1
year), and obese vs. non-obese participants (define
according to the body mass index) (Table 3). In three stu-
dies [26,27,30] carried out on obese subjects whose body
mass index was greater than 30 kg/m
2, pooled mean net
change of LDL-C was significant increase (3.46 mg/dl,
0.17 to 6.76); while none of the results was statistically
significant in normal weight subjects. Studies with longer
duration (> 1 year) [23,31] showed a significant reduction
in HDL-C (-2.01 mg/dl, -3.83 to -0.18) while trials of
short duration (≤ 1 year) showed a significant increase in
LDL-C (3.74 mg/dl, 0.58 to 6.90). Analysis by location in
which studies were carried out revealed nonsignificant
results. Sensitivity analysis that excluded the lower qual-
i t ys t u d i e s[ 2 2 , 2 3 ]s h o w e ds imilar effects of vitamin D
supplement on lipid profiles (Table 3).
The potential publication bias was examined by plot-
ting sample size versus mean net change for lipid pro-
files of the studies included in our analysis. For all lipid
profiles, the plots showed a typical funnel shape and no
publication bias were found.
Discussion
In our meta-analysis of randomized controlled trials,
vitamin D supplementation provided a statistically sig-
nificant increase in LDL-C (3.23 mg/dl). There was also
a tendency towards an increase in TC (1.52 mg/dl) with
supplementation of vitamin D, and the reductions in
HDL-C (-0.14 mg/dl) and TG (-1.92 mg/dl) were both
nonsignificant. The effect of vitamin D supplement on
serum LDL-C levels seemed more significant in obese
subjects and in studies with relatively shorter durations,
while studies with longer durations only showed a sig-
nificant reduction in HDL-C levels (-2.01 mg/dl). To
our knowledge, this is the first meta-analysis looking at
the effect of vitamin D supplement on lipid profiles.
Two previous systematic reviews summarized the effect
of vitamin D on serum lipid profiles [9,32], however, no
attempt to meta-analyze the data was made. By pooling
information from all qualified randomized controlled
studies, the results provided here are more precise and
powerful than those from the individual studies.
Observational studies have shown that high serum 25
(OH)D concentrations are associated with a favorable
l i p i dp r o f i l e[ 9 ] .I nt h es t u d yb yJ o r d ee ta l .[ 3 3 ]w h o
included 8018 nonsmoking subjects in the cross-sec-
tional study, there were highly significant positive asso-
ciations between serum 25(OH)D and serum TC,
HDL-C and LDL-C, and significant negative associa-
tions between serum 25(OH)D and both LDL-C/HDL-
C ratio and TG after adjustment for gender, age, BMI
and month of blood sampling. In consistent with this,
an increase in serum 25(OH)D was associated with a
significant decrease of serum TG in the longitudinal
Table 2 Serum levels of 25-hydroxyvitamin D in randomized trials with Vitamin D supplements
Trial Mean serum 25-hydroxyvitamin D3 (nmol/L)
Intervention group Control group
Initial levels Achieved levels Initial levels Achieved levels
Ljunghall et al. (1987) 75.5 85.7 79.6 110.2
Pfeifer et al. (2001) 25.65 64.84 24.63 44.36
Nagpal et al. (2009) 36.5 71.6 30.0 30.6
Zittermann et al. (2009) 30.0 85.5 30.3 42.0
Jorde et al. (a). (2010) 56.7 99.5 58.8 57.2
Jorde et al. (b). (2010) 58.7 138.0 58.8 57.2
Witham et al. (a). (2010) 41.0 63.0 45.0 54.0
Witham et al. (b). (2010) 48.0 79.0 45.0 54.0
Witham et al. (2010) 38.7 51.0 37.8 40.0
Maki et al. (2011) 64.4 76.1 67.9 66.7
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these findings are provocative, it is important to
understand the inherent limitations of observational
studies. Associations found in cross-sectional studies
are no proof of a causal relationship. Some common
factors may be attributed to both the high serum 25
(OH)D levels and favorable lipid profile. Individuals
with habits of exercising outside frequently and eating
nutritious food, which would elevate 25(OH)D levels,
may have other healthy habits which could favorably
affect lipid profiles. Therefore, intervention studies are
needed to detect a causal relationship between 25(OH)
D levels and lipids.
So far merely a few such intervention studies have
been reported and the results provided by them are
divergent. In addition, these studies are heterogeneous
with respect to vitamin D dose, study duration, and the
characteristics of subjects. In particular, the wide varia-
tion in the amount and formulation of supplemental
vitamin D may be the most important contributor to
the heterogeneity found in our results. To achieve 25
(OH)D levels above 75 nmol/L, the recommended level
Figure 2 Forest plots depicting the effect of vitamin D supplement on low-density lipoprotein (LDL) cholesterol. IV, inverse variance;
fixed, fixed effects model; CI, confidence interval.
Figure 3 Forest plots depicting the effect of vitamin D supplement on total cholesterol. IV, inverse variance; fixed, fixed effects model; CI,
confidence interval.
Wang et al. Lipids in Health and Disease 2012, 11:42
http://www.lipidworld.com/content/11/1/42
Page 5 of 9for several health outcomes [34], the daily intake of at
least 1000 IU (40 ug) vitamin D (cholecalciferol) would
be required. Most of the studies included in this analysis
used a high dosage of vitamin D (>/= 1000 IU) resulting
in significantly elevated 25(OH)D levels after the treat-
ment (Table 2). Notably, as the active form of vitamin
D, 1,25-dihydroxyvitamin D (1,25-D) is considered to be
more appropriate than 25(OH)D for assessing the links
between vitamin D and lipids [35]. It has been shown
that 25(OH)D and 1,25-D had similar but independent
biological effects. Unfortunately, few studies reported
baseline 1,25-D levels and its changes after the interven-
t i o n .A sar e s u l t ,i ti sn o tp o s s i b l et oe v a l u a t et h e
treatment effects of vitamin D on 1,25-D and the rela-
tionship between 1,25-D and lipids. Furthermore, not all
included studies used vitamin D3 as supplementation.
One study [29] used vitamin D2 and two other studies
[22,31] used alpha-calcidol. Vitamin D2 is less bioactive
than vitamin D3, whereas alpha-calcidol is a direct pre-
cursor of 1,25-D. These differences make a direct com-
parison of study results difficult.
Subgroup analyses by duration of intervention
revealed that vitamin D treatment has a more obvious
effect on LDL-C in the shorter duration studies. This
may be because longer duration studies are associated
with poor compliance of the subjects. On the other
Figure 4 Forest plots depicting the effect of vitamin D supplement on high-density lipoprotein (HDL) cholesterol. IV, inverse variance;
fixed, fixed effects model; CI, confidence interval.
Figure 5 Forest plots depicting the effect of vitamin D supplement on triglycerides. IV, inverse variance; fixed, fixed effects model; CI,
confidence interval.
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reduction in HDL-C levels. It is in agreement with the
fact that in vitamin D receptor knockout mice, there are
higher HDL-C levels and hepatic apoA-I mRNA expres-
sion relative to wild type mice [36]. Experiments in cul-
tured human hepatocytes also showed the metabolites
of vitamin D had a potent inhibitory effect on apoA-I
production and decreased both apoA-I secretion and
apoA-I mRNA levels [37,38].
It is reasonable to speculate that the treatment effects
of vitamin D are influenced by its baseline levels and
the increment in blood levels. However, it was not pos-
sible to assess the effect of baseline vitamin D status on
lipids profile from this meta-analysis, as the populations
among individual studies were heterogeneous. In addi-
tion, different geographical latitudes of the study sites
might have further complicated the issue of baseline
value of vitamin D, but the subgroup analysis by study
sites revealed nonsignificant results.
Although we have excluded the studies that focused
on patients in hemodialysis states, other confounders
that may have an unexpected influence on lipids could
not be eliminated. Among them, obesity is always asso-
ciated with dyslipidemia which includes high levels of
TG and LDL-C and low levels of HDL-C [39]. Addition-
ally, obesity may have an effect on vitamin D metabo-
lism because adipose tissue in obese subjects
preferentially uptakes vitamin D [40]. Therefore, we
conducted a subgroup analyses by the weight of subjects
and it showed a greater increase in serum LDL-C con-
centrations in obese subjects. However, there was no
significant effect in the normal weight subjects.
Our review has several limitations. First, we found few
eligible studies and none of them were sufficiently pow-
ered because they had relatively small numbers of parti-
cipants. Second, most participants included in our
studies were non-Hispanic White and elderly which lim-
its the applicability of our results to other groups in the
whole population. Third, as with any meta-analysis, the
potential for publication bias needs to be discussed.
However, the visual inspection of funnel plots suggests
that the presence of publication bias in this meta-analy-
s i si sl e s sl i k e l y .F i n a l l y ,n o n eo ft h es t u d i e si n c l u d e di n
our analysis were specifically designed to evaluate the
effect of vitamin D on serum lipids and none had hyper-
lipemia as an inclusion criterion. For all of these rea-
sons, the results derived from this meta-analyses should
be treated with considerable caution.
Conclusion
To date, evidence from randomized, controlled trials
indicated that vitamin D supplementation could increase
LDL cholesterol concentrations, but does not appear to
significantly affect total cholesterol, HDL cholesterol
and triglycerides. The lipid modulating effects of vitamin
D supplement should be further investigated through
large-scale, randomized trials with adequate doses which
can effectively elevated the active form of vitamin D in
plasma and with proper population which has hyperlipe-
mia as an inclusion criterion.
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Table 3 Results of subgroup and sensitivity analyses for evaluating the effect of vitamin D on lipid profile
Variables Total cholesterol LDL-C HDL-C Triglycerides
Mean difference (mg/dl) with 95% confidence interval and P value
Weight of subjects
Obesity[26,27,30] 3.22 [-0.70, 7.14]
P = 0.11
3.46 [0.17, 6.76]
P = 0.04
0.22 [-0.80, 1.23]
P = 0.68
-4.38 [-11.52, 2.76]
P = 0.23
Normal[22-25,28,29] -0.68 [-5.12, 3.77]
P = 0.77
2.77 [-1.82, 7.36]
P = 0.24
-0.97 [-2.53, 0.59]
P = 0.22
2.83 [-7.10, 12.76]
P = 0.58
Interventional duration
> 1 year[23,31] -0.26 [-6.05, 5.54]
P = 0.93
1.92 [-3.11, 6.95]
P = 0.45
-2.01 [-3.83, -0.18]
P = 0.03
0.96 [-10.01, 11.92]
P = 0.86
≤ 1 year[22,24-30] 2.13 [-1.28, 5.54]
P = 0.22
3.74 [0.58, 6.90]
P = 0.02
0.38 [-0.58, 1.34]
P = 0.44
-3.04 [-9.87, 3.79]
P = 0.38
Location of studies
High latitude area [22,23,27] 2.99 [-0.84, 6.81]
P = 0.13
3.12 [-0.39, 6.63]
P = 0.08
-0.04 [-1.23, 1.15]
P = 0.95
-2.30 [-10.02, 5.42]
P = 0.56
Middle and low latitude area[24-26,28-31] -0.60 [-5.20, 3.99]
P = 0.8
3.38 [-0.76, 7.52]
P = 0.11
-0.24 [-1.47, 0.98]
P = 0.7
-1.43 [-10.21, 7.34]
P = 0.75
Sensitivity analyses
Excluding low quality studies (Jadad < 4) [22,23] 1.32 [-1.80,4.45]
P = 0.41
3.05 [0.24, 5.86]
P = 0.03
-0.14 [-1.03, 0.75]
P = 0.75
-1.44 [-7.74, 4.86]
P = 0.65
Wang et al. Lipids in Health and Disease 2012, 11:42
http://www.lipidworld.com/content/11/1/42
Page 7 of 9Author details
1Department of Cardiology, the Second Xiangya Hospital, Central South
University, Changsha 410011, Hunan, People’s Republic of China.
2Department of Pulmonary, Xiangya Hospital, Central South University,
Changsha 410011, Hunan, People’s Republic of China.
Authors’ contributions
HW and NX conducted the literature search, data extraction and quality
assessment. YY and DQP conceived the study, its design and drafted the
manuscript. All authors read and approved the final manuscript.
Received: 4 February 2012 Accepted: 20 March 2012
Published: 20 March 2012
References
1. Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJ: Global and
regional burden of disease and risk factors, 2001: systematic analysis of
population health data. Lancet 2006, 367(9524):1747-1757.
2. Holick MF: Vitamin D deficiency. N Engl J Med 2007, 357(3):266-281.
3. Wang TJ, Pencina MJ, Booth SL, Jacques PF, Ingelsson E, Lanier K,
Benjamin EJ, D’Agostino RB, Wolf M, Vasan RS: Vitamin D deficiency and
risk of cardiovascular disease. Circulation 2008, 117(4):503-511.
4. Parker J, Hashmi O, Dutton D, Mavrodaris A, Stranges S, Kandala NB,
Clarke A, Franco OH: Levels of vitamin D and cardiometabolic disorders:
systematic review and meta-analysis. Maturitas 2010, 65(3):225-236.
5. Wang L, Manson JE, Song Y, Sesso HD: Systematic review: Vitamin D and
calcium supplementation in prevention of cardiovascular events. Ann
Intern Med 2010, 152(5):315-323.
6. Mithal A, Wahl DA, Bonjour JP, Burckhardt P, Dawson-Hughes B, Eisman JA,
El-Hajj Fuleihan G, Josse RG, Lips P, Morales-Torres J: Global vitamin D
status and determinants of hypovitaminosis D. Osteoporos Int 2009,
20(11):1807-1820.
7. Lee JH, O’Keefe JH, Bell D, Hensrud DD, Holick MF: Vitamin D deficiency
an important, common, and easily treatable cardiovascular risk factor? J
Am Coll Cardiol 2008, 52(24):1949-1956.
8. Zittermann A, Schleithoff SS, Koerfer R: Putting cardiovascular disease and
vitamin D insufficiency into perspective. Br J Nutr 2005, 94(4):483-492.
9. Jorde R, Grimnes G: Vitamin D and metabolic health with special
reference to the effect of vitamin D on serum lipids. Prog Lipid Res 2011,
50(4):303-312.
10. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ,
McQuay HJ: Assessing the quality of reports of randomized clinical trials:
is blinding necessary? Control Clin Trials 1996, 17(1):1-12.
11. Follmann D, Elliott P, Suh I, Cutler J: Variance imputation for overviews of
clinical trials with continuous response. J Clin Epidemiol 1992,
45(7):769-773.
12. Andersen R, Brot C, Mejborn H, Molgaard C, Skovgaard LT, Trolle E,
Ovesen L: Vitamin D supplementation does not affect serum lipids and
lipoproteins in Pakistani immigrants. Eur J Clin Nutr 2009, 63(9):1150-1153.
13. Myrup B, Jensen GF, McNair P: Cardiovascular risk factors during
estrogen-norethindrone and cholecalciferol treatment. Arch Intern Med
1992, 152(11):2265-2268.
14. Gannage-Yared MH, Azoury M, Mansour I, Baddoura R, Halaby G, Naaman R:
Effects of a short-term calcium and vitamin D treatment on serum
cytokines, bone markers, insulin and lipid concentrations in healthy
post-menopausal women. J Endocrinol Investig 2003, 26(8):748-753.
15. Major GC, Alarie F, Dore J, Phouttama S, Tremblay A: Supplementation
with calcium + vitamin D enhances the beneficial effect of weight loss
on plasma lipid and lipoprotein concentrations. Am J Clin Nutr 2007,
85(1):54-59.
16. Schwartz JB: Effects of vitamin D supplementation in atorvastatin-treated
patients: a new drug interaction with an unexpected consequence. Clin
Pharmacol Ther 2009, 85(2):198-203.
17. Rajpathak SN, Xue X, Wassertheil-Smoller S, Van Horn L, Robinson JG, Liu S,
Allison M, Martin LW, Ho GYF, Rohan TE: Effect of 5 y of calcium plus
vitamin D supplementation on change in circulating lipids: Results from
the women’s health initiative. Am J Clin Nutr 2010, 91(4):894-899.
18. Yeksan M, Turk S, Polat M, Cigli A, Erdogan Y: Effects of 1,25 (OH)2D3
treatment on lipid levels in uremic hemodialysis patients. Int J Artif
Organs 1992, 15(12):704-707.
19. Khajehdehi P: Effect of vitamins on the lipid profile of patients on
regular hemodialysis. Scand J Urol Nephrol 2000, 34(1):62-66.
20. Khajehdehi P, Taheri S: Effect of oral calcitriol pulse therapy on the lipid,
calcium, and glucose homeostasis of hemodialysis-patients: its safety in
a combination with oral calcium carbonate. J Ren Nutr Offic J Counc Ren
Nutr Nat Kidney Found 2003, 13(2):78-83.
21. Bonakdaran S, Ayatollahi H, Mojahedi MJ, Sharifipoor F, Shakeri M: Impact
of treatment with oral calcitriol on glucose intolerance and dyslipidemia
(s) in hemodialysis patients. Saudi J Kidney Dis Transplant Offic Publ Saudi
Center Organ Transplant Saudi Arabia 2008, 19(6):942-947.
22. Ljunghall S, Lind L, Lithell H, Skarfors E, Selinus I, Sorensen OH, Wide L:
Treatment with one-alpha-hydroxycholecalciferol in middle-aged men
with impaired glucose tolerance-a prospective randomized double-blind
study. Acta Med Scand 1987, 222(4):361-367.
23. Heikkinen AM, Tuppurainen MT, Niskanen L, Komulainen M, Penttila I,
Saarikoski S: Long-term vitamin D3 supplementation may have adverse
effects on serum lipids during postmenopausal hormone replacement
therapy. Eur J Endocrinol 1997, 137(5):495-502.
24. Pfeifer M, Begerow B, Minne HW, Nachtigall D, Hansen C: Effects of a
short-term vitamin D(3) and calcium supplementation on blood
pressure and parathyroid hormone levels in elderly women. J Clin
Endocrinol Metab 2001, 86(4):1633-1637.
25. Nagpal J, Pande JN, Bhartia A: A double-blind, randomized, placebo-
controlled trial of the short-term effect of vitamin D3 supplementation
on insulin sensitivity in apparently healthy, middle-aged, centrally obese
men. Diabet Med J Br Diabet Assoc 2009, 26(1):19-27.
26. Zittermann A, Frisch S, Berthold HK, Gotting C, Kuhn J, Kleesiek K, Stehle P,
Koertke H, Koerfer R: Vitamin D supplementation enhances the beneficial
effects of weight loss on cardiovascular disease risk markers. Am J Clin
Nutr 2009, 89(5):1321-1327.
27. Jorde R, Sneve M, Torjesen P, Figenschau Y: No improvement in
cardiovascular risk factors in overweight and obese subjects after
supplementation with vitamin D3 for 1 year. J Intern Med 2010,
267(5):462-472.
28. Witham MD, Dove FJ, Dryburgh M, Sugden JA, Morris AD, Struthers AD:
The effect of different doses of vitamin D(3) on markers of vascular
health in patients with type 2 diabetes: a randomised controlled trial.
Diabetologia 2010, 53(10):2112-2119.
29. Witham MD, Dove FJ, Sugden JA, Doney AS, Struthers AD: The effect of
vitamin D replacement on markers of vascular health in stroke patients -
A randomised controlled trial. Nutr Metab Cardiovasc Dis 2010.
30. Maki KC, Rubin MR, Wong LG, McManus JF, Jensen CD, Lawless A: Effects
of vitamin D supplementation on 25-hydroxyvitamin D, high-density
lipoprotein cholesterol, and other cardiovascular disease risk markers in
subjects with elevated waist circumference. Int J Food Sci Nutr 2011,
62(4):318-327.
31. Sai AJ, Gallagher JC, Fang X: Effect of hormone therapy and calcitriol on
serum lipid profile in postmenopausal older women: Association with
estrogen receptor-(alpha) genotypes. Menopause 2011, 18(10):1101-1112.
32. Zittermann A, Gummert JF, Borgermann J: The role of vitamin D in
dyslipidemia and cardiovascular disease. Curr Pharm Des 2011,
17(9):933-942.
33. Jorde R, Figenschau Y, Hutchinson M, Emaus N, Grimnes G: High serum 25-
hydroxyvitamin D concentrations are associated with a favorable serum
lipid profile. Eur J Clin Nutr 2011, 64(12):1457-1464.
34. Bischoff-Ferrari HA, Giovannucci E, Willett WC, Dietrich T, Dawson-Hughes B:
Estimation of optimal serum concentrations of 25-hydroxyvitamin D for
multiple health outcomes. Am J Clin Nutr 2006, 84(1):18-28.
35. Karhapaa P, Pihlajamaki J, Porsti I, Kastarinen M, Mustonen J, Niemela O,
Kuusisto J: Diverse associations of 25-hydroxyvitamin D and 1,25-dihydroxy-
vitamin D with dyslipidaemias. J Intern Med 2010, 268(6):604-610.
36. Wang JH, Keisala T, Solakivi T, Minasyan A, Kalueff AV, Tuohimaa P: Serum
cholesterol and expression of ApoAI, LXRbeta and SREBP2 in vitamin D
receptor knock-out mice. J Steroid Biochem Mol Biol 2009, 113(3-
5):222-226.
37. Wehmeier K, Beers A, Haas MJ, Wong NC, Steinmeyer A, Zugel U,
Mooradian AD: Inhibition of apolipoprotein AI gene expression by 1, 25-
dihydroxyvitamin D3. Biochim Biophys Acta 2005, 1737(1):16-26.
38. Wehmeier KR, Alamir AR, Sultan S, Haas MJ, Wong NC, Mooradian AD: 24,
25-dihydroxycholecalciferol but not 25-hydroxycholecalciferol
Wang et al. Lipids in Health and Disease 2012, 11:42
http://www.lipidworld.com/content/11/1/42
Page 8 of 9suppresses apolipoprotein A-I gene expression. Life Sci 2011, 88(1-
2):110-116.
39. Poirier P, Giles TD, Bray GA, Hong Y, Stern JS, Pi-Sunyer FX, Eckel RH:
Obesity and cardiovascular disease: pathophysiology, evaluation, and
effect of weight loss: an update of the 1997 American Heart Association
Scientific Statement on Obesity and Heart Disease from the Obesity
Committee of the Council on Nutrition, Physical Activity, and
Metabolism. Circulation 2006, 113(6):898-918.
40. Wortsman J, Matsuoka LY, Chen TC, Lu Z, Holick MF: Decreased
bioavailability of vitamin D in obesity. Am J Clin Nutr 2000, 72(3):690-693.
doi:10.1186/1476-511X-11-42
Cite this article as: Wang et al.: Influence of vitamin D supplementation
on plasma lipid profiles: A meta-analysis of randomized controlled
trials. Lipids in Health and Disease 2012 11:42.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Wang et al. Lipids in Health and Disease 2012, 11:42
http://www.lipidworld.com/content/11/1/42
Page 9 of 9